Anticancer Drug Use and Out-Of-Pocket Money Burden in Korean Cancer Patients: A questionnaire Study

국내 암환자의 항암제 사용 및 본인부담비용에 대한 실태조사

  • 김해숙 (숙명여자대학교 약학대학) ;
  • 장진경 (숙명여자대학교 약학대학) ;
  • 손현순 (숙명여자대학교 약학대학)
  • Received : 2012.07.02
  • Accepted : 2012.09.13
  • Published : 2012.09.30

Abstract

In recent years, national health insurance(NHI) coverage had been expanded gradually for cancer as a severe disease requiring high level of medical expenditure, to reduce patient's financial burden. But, subjective burdens level for out-of-pocket(OOP) money expense are still considerable owing to high medical cost and decent numbers of services not covered by benefit plan. This study aimed to investigate OOP medical expenditures and identify factors influencing subjective financial burden in cancer patients. A 28-items questionnaire for self-reporting by responders was designed to satisfy study goal and finalized following by one pilot study and experts' verification process. Subjects were enrolled during July to October 2010 through regular meetings organized by five patient or patient-advocacy groups had acknowledged the study purpose. Subjects who aged 20 or more, have histories of cancer diagnosis and anticancer drug use, and voluntarily agreed to participate in this study were recruited. Total 107 subjects included in the analysis have cancer lesions in breast, colon, kidney, liver or stomach at the stages from I to IV. Approximately 73% of them has passed less than 5 years since cancer diagnosis. For the OOP medical expenditure regarding cancer, less 6 million won was in 31%, 6-15 million won in 35% and more than 15 million won in 28% of responders, and more than half responders(58%) felt financial burden subjectively. 63% of responders had subscribed commercial insurances, resulting in money receipts of more than 10 million won since cancer diagnoses in 76% of responders. Logistic regression results showed significant differences in subjective OOP financial burden level depending on gender, household income level, benefit type, commercial insurance money receipt degree, year cancer diagnosed, cancer lesion, therapy type, duration of anticancer drug use, drug listing in national formulary, total OOP medical expenditure and total OOP anticancer drug expense. They had mixed feelings both wishes to expand NHI coverage to reduce financial burden(70%) and no willingness to increase premium(59%). This result suggested that NHI might direct future strategies to reduce absolute total OOP medical cost and expand benefit plan coverage in higher burden groups in particular.

Keywords

References

  1. Ministry of Health and Welfare. Press Release: 암환자 본인 부담금 5% 특례제도. http://www.mw.go.kr/front/al/sal0301- vw.jsp?PAR_MENU_ID=04&MENU_ID=0403&CONT_SE Q=239755&page=110&CREATE_DATE2=target=_blank. 2010. 8. 24
  2. Cancer Facts & Figures 2011. Ministry of Health & Welfare.National Cancer Center, 2011
  3. Cancer Facts & Figures 2010. Ministry of Health & Welfare.National Cancer Center, 2010
  4. Choi YS, Baek SJ, Lim ES, Lee HY, Jang HJ. 2009 건강 보험환자 진료비 실태조사. National Health Insurance Corporation. 2010.
  5. Yoo KK. Cost trends of Chemotherapy and Survival Rate - Focusing on Cancer of the Liver, Colon, the Stomach, Breast, the Pancreas, and the Lungs. Korea University School of Public Health, 2006.
  6. Yoon YH. 암정복추진연구개발사업 최종보고서: 말기암환자 의료비 지출실태 분석. Ministry of Health and Welfare. 2005.
  7. Kim JH. Research Report: 암진단부터 사망까지 의료비 추계 및 진료실태 - 2001년-2005년 8대암 등록환자를 중심으로. Health Insurance Review and Assessment Service. 2010.
  8. Park EC. Research Report: 암검진의 효과 평가 및 암 비용 연구. National Cancer Center. 2006.
  9. National Health Insurance Corporation.Health Insurance Review and Assessment Service. 2009 NHI Statistics. 2010.
  10. Kukminilbo. Press Release. http://news.kukinews.com/article/ view.asp?page=1&gCode=kmi&arcid=0005887944&cp=du. 2012. 7. 30